The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
Given the variable protective efficacy generated by Mycobacterium bovis BCG (Bacillus Calmette-Guérin), there is a concerted effort worldwide to develop better vaccines that could be used to reduce the burden of tuberculosis. Rational attenuated mutants of Mycobacterium tuberculosis are vaccine candidates that offer some potential in this area. In this paper, we will discuss the molecular methods used to generate mutant mycobacteria, as well as the results obtained with some of these strains, in terms of attenuation, immunogenicity and level of protection, when compared with the conventional BCG vaccine in diverse animal models. Tuberculosis vaccine candidates based on safe and live mycobacterial mutants could be promising candidates.
Experimental Pathology Section, Pathology Department, National Institute of Medical Sciences and Nutrition Salvador Zubiràn, Vasco de Quiroga 15, Tlalpan, Mexico City, Mexico. rhpando@quetzal.innsz.mx
R
R
Hernàndez Pando
L D
LD
Aguilar
E
E
Infante
A
A
Cataldi
F
F
Bigi
C
C
Martin
B
B
Gicquel
D000818:Animals; D001500:BCG Vaccine; D004195:Disease Models, Animal; D016296:Mutagenesis; D009169:Mycobacterium tuberculosis / Q000235:genetics* / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology
D001500:BCG Vaccine; D032581:Tuberculosis Vaccines; D014613:Vaccines, Attenuated